Insider Transactions in Q1 2025 at Madrigal Pharmaceuticals, Inc. (MDGL)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2025
|
Shannon T Kelley General Counsel |
SELL
Open market or private sale
|
Direct |
415
-5.39%
|
$139,025
$335.0 P/Share
|
|
Mar 03
2025
|
Mardi Dier SVP and CFO |
SELL
Open market or private sale
|
Direct |
1,961
-11.72%
|
$635,364
$324.72 P/Share
|
|
Mar 03
2025
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,834
-2.11%
|
$592,382
$323.86 P/Share
|
|
Feb 28
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
1,227
-12.86%
|
$418,407
$341.27 P/Share
|
|
Feb 27
2025
|
William John Sibold President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+32.4%
|
-
|
|
Feb 27
2025
|
Kenneth Bate Director |
SELL
Open market or private sale
|
Direct |
20,000
-21.4%
|
$7,100,000
$355.92 P/Share
|
|
Feb 27
2025
|
Kenneth Bate Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+31.84%
|
$1,220,000
$61.86 P/Share
|
|
Feb 27
2025
|
James M Daly Director |
SELL
Open market or private sale
|
Direct |
15,470
-38.4%
|
$5,368,090
$347.74 P/Share
|
|
Feb 27
2025
|
James M Daly Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,470
+35.54%
|
$1,361,360
$88.06 P/Share
|
|
Jan 24
2025
|
Carole Huntsman Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
347
-3.22%
|
$116,245
$335.24 P/Share
|
|
Jan 24
2025
|
William John Sibold President and CEO |
SELL
Open market or private sale
|
Direct |
1,584
-2.83%
|
$530,640
$335.24 P/Share
|
|
Jan 24
2025
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
648
-0.14%
|
$217,080
$335.24 P/Share
|
|
Jan 24
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
103
-2.04%
|
$34,505
$335.24 P/Share
|
|
Jan 17
2025
|
Shannon T Kelley General Counsel |
SELL
Open market or private sale
|
Direct |
277
-3.47%
|
$75,621
$273.41 P/Share
|
|
Jan 17
2025
|
Rebecca Taub Pres., R&D, and CMO |
SELL
Open market or private sale
|
Direct |
1,689
-0.37%
|
$461,097
$273.41 P/Share
|
|
Jan 17
2025
|
Robert E. Waltermire Senior VP, Chief Pharma Dev. |
SELL
Open market or private sale
|
Direct |
442
-8.04%
|
$120,666
$273.41 P/Share
|